RxDoctor Payments DataLook up a doctor →

Parminder Singh, MD

Internal Medicine · Marion, OHNPI 1598756546

Payments from drug & device makers

$689,836in general payments, 2019–2025

Across 551 payments — averaging $1251.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$294K
  • AstraZeneca$156K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$129K
  • Amgen$60K
  • Alnylam Pharmaceuticals Inc.$43K
  • Novartis$2K
  • plus $6K from 36 others
$4,798in research payments, 2019–2025

Across 27 payments — averaging $177.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$3K
  • Regeneron$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim International GmbH214$293,746
AstraZeneca37$156,438
Boehringer Ingelheim Pharma GmbH & Co.kg10$129,005
Amgen7$59,840
Alnylam Pharmaceuticals Inc.12$42,883
Novartis3$1,675
AbbVie(2 entities)67$1,148
ZOLL Respicardia, Inc.2$845
Pfizer49$486
Veryan Medical Incorporated3$457
Boston Scientific5$455
Lilly USA, LLC23$434
Novo Nordisk26$370
Insulet Corporation8$276
GSK18$272
Corvista Health, Inc.2$216
Corcept Therapeutics7$124
Johnson & Johnson8$122
Exact Sciences6$107
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$102
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$97
Astellas Pharma US Inc6$91
Medicomp Inc3$81
Abbott1$73
Otsuka America Pharmaceutical, Inc.4$66
Avanos Medical1$57
Lundbeck LLC2$51
Vanda Pharmaceuticals Inc.2$48
Sanofi-aventis U.S. LLC3$40
Cardiva Medical, Inc.1$28
Lifescan, Inc.1$26
Indivior Inc.1$21
Daiichi Sankyo Inc.1$20
Teva Pharmaceuticals USA, Inc.1$17
Amarin Pharma, Inc.1$17
Chiesi USA, Inc.1$16
Takeda Pharmaceuticals U.S.A., Inc.1$15
UCB, Inc.1$14
Ascensia Diabetes Care US Inc.1$14
E.r. Squibb & Sons, L.L.C.1$14
Merck1$14
Ironwood Pharmaceuticals, Inc1$14

How this compares

$689,836 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio →

Medicare billing

Part B allowed, 2024
$825,061
Medicare patients
902
Services billed
13,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Marion

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →